Results 21 to 30 of about 260,886 (316)

Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy

Cancer Management and Research, 2023
Wei-Fan Ou,1 Pei-Ya Liao,1 Yu-Wei Hsu,2,3 Yen-Hsiang Huang,1,4– 6 Kuo-Hsuan Hsu,6,7 Jeng-Sen Tseng,1,4– 6,8 Gee-Chen Chang,4,9– 11 Tsung-Ying Yang1,6,12 1Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital ...
Ou WF, Liao PY, Hsu YW, Huang YH, Hsu KH, Tseng JS, Chang GC, Yang TY   +7 more
doaj  

Epidermal growth factor receptor-mutated non-small-cell lung cancer: A primer on contemporary management

Cancer Research, Statistics, and Treatment, 2019
Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic chemotherapy, which resulted in a median overall survival of 7.9 months.
Akhil Rajendra, Vanita Noronha, Amit Joshi, Vijay Maruti Patil, Nandini Menon, Kumar Prabhash   +5 more
doaj   +1 more source

Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series

Cancer Research, Statistics, and Treatment, 2021
Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones.
Sandip Ganguly, Joydeep Ghosh, Anisha Gehani, Archisman Basu, Meheli Chatterjee, Deepak Dabkara, Bivas Biswas   +6 more
doaj   +1 more source

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands [PDF]

, 2021
This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness) correspond to outcomes in clinical trials (efficacy) and to look into factors that might explain an efficacy-effectiveness (EE) gap.
The Santeon NSCLC Study Group
core  

The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer

Cancer Biology & Medicine, 2022
Objective: The novel compound GCJ-490A has been discovered as a pan-histone deacetylase (HDAC) inhibitor that exerts potent inhibitory activity against HDAC1, HDAC3, and HDAC6.
Ting He, Yinglei Gao, Yanfen Fang, Yangming Zhang, Shuwei Zhang, Fajun Nan, Jian Ding, Yi Chen   +7 more
doaj   +1 more source

The Accuracy of Clinical Staging of Stage I-IIIa Non-Small Cell Lung Cancer An Analysis Based on Individual Participant Data [PDF]

, 2018
BACKGROUND: Clinical staging of non-small cell lung cancer (NSCLC) helps determine the prognosis and treatment of patients; few data exist on the accuracy of clinical staging and the impact on treatment and survival of patients.
Dautzenberg, Bertrand, Vallieres, Eric, van Meerbeeck, Jan, Waller, David, Arriagada, Rodrigo, Scagliotti, Giorgio, Tsuboi, Masahiro, Yang, Xue-Ning, Auperin, Anne, Pignon, Jean-Pierre, Navani, Neal, Parmar, Mahesh K. B., Rydzewska, Larysa H. M., Johnson, David H., Stewart, Lesley A., Westeel, Virginie, Tierney, Jayne F., Knuuttila, Aija, Stewart, Lesley, Gilligan, David, Wu, Yi-Long, Stephens, Richard, Burdett, Sarah, Le Chevalier, Thierry, Bunn, Paul A., Le Pechoux, Cecile, Groen, Harry, Rosell, Rafael, Roth, Jack, NSCLC Meta Anal Collaborative Grp, Fisher, David J.   +30 more
core   +1 more source

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. [PDF]

, 2022
Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis.
Gopalakrishnan, Abilash Valsala, Dey, Abhijit, Wilson, Cornelia M, George, Alex, Rajanikant, Golgodu Krishnamurthy, Wanjari, Uddesh Ramesh, Al-Yozbaki, Minnatallah, Dewanjee, Saikat, John, Mithun Chacko, Renu, Kaviyarasi, Mukherjee, Anirban Goutam, Padinharayil, Hafiza, Sanyal, Rupa, Varghese, Jinsu   +13 more
core   +1 more source

lncRNA SLC9A3-AS1 Promotes Oncogenesis of NSCLC via Sponging microRNA-760 and May Serve as a Prognosis Predictor of NSCLC Patients

Cancer Management and Research, 2022
Xiuming Huang,* Mingfang Huang,* Minbiao Chen, Xianshan Chen Department of Thoracic Surgery, Hainan General Hospital, Haikou, Hainan, 570311, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xianshan ...
Huang X, Huang M, Chen M, Chen X
doaj  

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression

Open Medicine, 2021
Non-small cell lung cancer (NSCLC) is a malignant tumor with the highest mortality rate in our country. It has been found in many studies that microRNA-4521 (miR-4521) is abnormally expressed and plays a role in clear cell renal cell carcinoma and other ...
Sun Butong, Cong Dan, Chen Kang, Bai Yuansong, Li Jun   +4 more
doaj   +1 more source

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation

Cancer Management and Research, 2021
Tianxiang Zhang,1 Wei Li,2 Meng Gu,1 Ziyu Wang,1 Shijie Zhou,2 Xuefeng Hao,1 Weiying Li,1 Shaofa Xu1 1Department of Cellular and Molecular Biology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research ...
Zhang T, Li W, Gu M, Wang Z, Zhou S, Hao X, Li W, Xu S   +7 more
doaj